AURA News and Press, Aura Biosciences Inc.

(NewsDirect) Aura Energy Ltd (ASX:AEE, AIM:AURA) MD Dave Woodall speaks with Proactive soon after announcing the company has raised A$10 million via a share placement at A$0.185 per share to advance development across the company’s project portfolio. The placement was supported by exis...

(NewsDirect) Aura Energy Limited (ASX: AEE, AIM: AURA) CEO Dave Woodall responds to a recent report that the Industry Committee of the Swedish parliament has voted to reject a number of private members’ motions supporting an immediate lifting of the ban on uranium mining in Sweden. He ...

2023-03-15 17:12:04 ET Aura Biosciences press release ( NASDAQ: AURA ): FY GAAP EPS of -$1.96 misses by $0.02 . As of December 31, 2022, Aura had cash and cash equivalents and marketable securities totaling $188.8 million. Aura believes its current cash and cash equiva...

U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Belzupacap Sarotalocan (bel-sar) for the Treatment of Choroidal Metastasis, Bel-sar’s Second Ocular Oncology Indication to Receive this Designation Global Phase 3 Trial in Primary Choroidal Melanoma on Track ...

Oncology-focused biotech Aura Biosciences ( NASDAQ: AURA ) added ~3% pre-market Thursday after updating interim results from the company’s Phase 2 trial for eye cancer therapy Belzupacap Sarotalocan (bel-sar) in choroidal melanoma. The study is designed to evaluate bel-sar,...

Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the presentation of positive interim Phase 2 safety and efficacy data of be...

(NewsDirect) Aura Energy Ltd (ASX:AEE, AIM:AURA) MD Dave Woodall discusses with Proactive a 52% increase in measured and indicated resources at the Tiris Uranium Project in Mauritania. He says the immediate focus is now to work with in-country stakeholders, offtake providers, investors and fi...

Shares of clinical-stage biotech company Aura Biosciences (NASDAQ: AURA) were up 11.2% as of Thursday afternoon, according to data provided by S&P Global Market Intelligence . The stock closed last week at $10.13 and climbed to as high as $12.31 on Tuesday. Aura's 52-week low ...

Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the pricing of an underwritten public offering of 6,700,000 shares of its c...

Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the launch of an underwritten public offering of its common stock. All shar...